相关实验视频

Updated: Jun 11, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

通过CTLA4-Ig疗法抑制T细胞活动的上下文受限PD-(L) 1检查点激应

Ethan P Oxley¹, Nadia J Kershaw², Cynthia Louis²

¹Australian Centre for Blood Diseases, Monash University, 99 Commercial Road, Melbourne, VIC 3004, Australia.

|October 9, 2024

概括

细胞毒性T淋巴细胞相关蛋白4 (CTLA4) 免疫球蛋白 (Ig) 疗法阻断T细胞的共刺激. 这些疗法从抗原呈现细胞中最小释放PD-L1联体,限制它们的T细胞抑制作用.

科学领域:

免疫学免疫学免疫学
分子生物学分子生物学
细胞生物学细胞生物学

背景情况:

通过抗原呈现细胞 (APC) 上的CD80/CD86连接体对T细胞进行共刺激,对于预防自身免疫非常重要.
再组合CTLA4-Ig融合蛋白,像阿巴塔塞普特一样,用于通过阻断CD80/CD86来抑制T细胞反应.
以前的研究表明CTLA4-Ig可能会从APC中释放抑制性联体PD-L1,但其对T细胞抑制的贡献尚不清楚.

研究的目的:

调查CTLA4-Ig.通过PD-L1释放的程度和环境依赖性.
为了比较CTLA4-Ig引起的PD-L1释放与抗CD80抗体引起的PD-L1释放.
确定修改CTLA4-Ig结构是否会影响PD-L1解离和T细胞抑制.

主要方法:

使用的APC和CTLA4-Ig融合蛋白具有不同的CD80:PD-L1比率.
使用抗CD80抗体作为PD-L1释放的对照.
工程 CTLA4-Ig 变体与改变的二元化接口来评估结构影响.

主要成果:

CTLA4-Ig疗法显示PD-L1释放有限,明显低于抗CD80抗体.
通过CTLA4-Ig释放PD-L1在PC上CD80:PD-L1比率超过2:1时被抑制.
修改后的CTLA4-Ig变体保持了CD80结合,但没有解离PD-L1,表明在释放中具有结构性作用.

结论:

CTLA4-Ig介导的PD-L1释放取决于情境,并与CD80重定位有机联系.
通过CTLA4-Ig释放PD-L1的程度不足以显著促进PD-1通路激动和T细胞抑制.
通过CTLA4-Ig治疗性免疫抑制主要依赖于CD80/CD86阻断而不是PD-L1通路调节.

关键词:

CD8080 CD8080 CD8080 CD8080 CD8080 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD80 CD86 CD86 CD86 CD86 CD86 CD86 CD86 CD86 CD86 CD86 CD86 CD86 CD86 CD86 CD86 CD86 CD86 CD86 CD86 CP: 免疫学免疫学在 CTLA4-Ig 中.在PD-1中使用PD-1.在PD-L1中.一个T细胞细胞.这就是 abataceptcept.呈现抗原的细胞呈现抗原.这是自身免疫力.这是一种炎症炎症炎症炎症.

更多相关视频

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes

Directed Differentiation of Induced Pluripotent Stem Cells towards T Lymphocytes

Published on: May 14, 2012

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...